Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027
The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% during the forecast period. The growth of the market is projected to be driven by collaborations and agreements among market players for stem cell assay products & services, launch of new stem cell analysis systems such as flow cytometers and increase in R&D expenditure by biopharmaceutical and biotechnology companies.
The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021.
Cell viability assays help to determine the number of live and dead cells in a culture medium. The viability/cytotoxicity assays includes various types such as tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, and other viability/cytotoxicity assays. The cell viability/cytotoxicity market is likely to be driven by rise R&D spending on stem cell research, increase in demand for stem cell assays in drug discovery and development of new stem cell therapies..
The adult stem cells segment accounted for the largest share of the cell type segment in the stem cell assays market in 2021.
The adult stem cells account for the largest share of the stem cell assays market. The adult stem cells include mesenchymal stem cells, induced pluripotent stem cells, hematopoietic stem cells, umbilical cord stem cells, and neural stem cells. The growth of adult stems cells segment is driven by increasing usage of adult stem cells in regenerative medicine and development of advanced therapies.
Key players in the stem cell assays market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), PerkinElmer (US), Agilent Technologies (US), Promega Corporation (US), Cell Biolabs (US), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Bio-Techne Corporation (US), FUJIFILM Holdings Corporation (Japan), Charles River Laboratories (US), HemoGenix Inc. (US), Lonza Group (Switzerland), Takara Bio Inc. (Japan), Creative Bioarray (US), AAT Bioquest, Inc. (US), BPS Bioscience, Inc. (US), Enzo Biochem (US), PromoCell GmbH (Germany), Biotium (US), Geno Technology (US), Abcam plc (UK), and ReachBio Research Labs (US).
“Asia Pacific: The fastest-growing region in the stem cell assays market”
The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to rising prevalence of cancer & other diseases, increasing R&D spending on biopharmaceutical projects and focus on developing stem cell based therapies. In this region, China and Japan are the largest markets.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the stem cell assays market. It aims at estimating the size and future growth potential of the market across different segments such as the product, functionality, formulation and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.
The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021.
Cell viability assays help to determine the number of live and dead cells in a culture medium. The viability/cytotoxicity assays includes various types such as tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, and other viability/cytotoxicity assays. The cell viability/cytotoxicity market is likely to be driven by rise R&D spending on stem cell research, increase in demand for stem cell assays in drug discovery and development of new stem cell therapies..
The adult stem cells segment accounted for the largest share of the cell type segment in the stem cell assays market in 2021.
The adult stem cells account for the largest share of the stem cell assays market. The adult stem cells include mesenchymal stem cells, induced pluripotent stem cells, hematopoietic stem cells, umbilical cord stem cells, and neural stem cells. The growth of adult stems cells segment is driven by increasing usage of adult stem cells in regenerative medicine and development of advanced therapies.
Key players in the stem cell assays market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), PerkinElmer (US), Agilent Technologies (US), Promega Corporation (US), Cell Biolabs (US), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Bio-Techne Corporation (US), FUJIFILM Holdings Corporation (Japan), Charles River Laboratories (US), HemoGenix Inc. (US), Lonza Group (Switzerland), Takara Bio Inc. (Japan), Creative Bioarray (US), AAT Bioquest, Inc. (US), BPS Bioscience, Inc. (US), Enzo Biochem (US), PromoCell GmbH (Germany), Biotium (US), Geno Technology (US), Abcam plc (UK), and ReachBio Research Labs (US).
“Asia Pacific: The fastest-growing region in the stem cell assays market”
The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to rising prevalence of cancer & other diseases, increasing R&D spending on biopharmaceutical projects and focus on developing stem cell based therapies. In this region, China and Japan are the largest markets.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 80% and Demand Side - 20%
- By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
- By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%
- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- Danaher (US)
- Becton, Dickinson and Company (US)
- Bio-Rad Laboratories (US)
- PerkinElmer (US)
- Agilent Technologies (US)
- Promega Corporation (US)
- Cell Biolabs (US)
- Miltenyi Biotec (Germany)
- STEMCELL Technologies (Canada)
- Bio-Techne Corporation (US)
- FUJIFILM Holdings Corporation (Japan)
- Charles River Laboratories (US)
- HemoGenix Inc. (US)
- Lonza Group (Switzerland)
- Takara Bio Inc. (Japan)
- Creative Bioarray (US)
- AAT Bioquest, Inc. (US)
- BPS Bioscience, Inc. (US)
- Enzo Biochem (US)
- PromoCell GmbH (Germany)
- Biotium (US)
- Geno Technology (US)
- Abcam plc (UK)
- ReachBio Research Labs (US).
This report provides a detailed picture of the stem cell assays market. It aims at estimating the size and future growth potential of the market across different segments such as the product, functionality, formulation and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES, BY RESPONDENT, DESIGNATION, AND REGION
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 STEM CELL ASSAYS MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2021
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 6 STEM CELL ASSAYS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 7 STEM CELL ASSAYS MARKET (DEMAND SIDE):
GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
2.3.1 DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.4.1 COVID-19 ASSUMPTIONS
2.5 RISK ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 9 STEM CELL ASSAYS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 STEM CELL ASSAYS MARKET, BY CELL TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 11 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 12 STEM CELL ASSAYS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 13 STEM CELL ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF STEM CELL ASSAYS MARKET
4 PREMIUM INSIGHTS
4.1 STEM CELL ASSAYS MARKET OVERVIEW
FIGURE 15 RISING AWARENESS ABOUT THERAPEUTIC POTENCY OF
STEM CELLS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2021)
FIGURE 16 INSTRUMENTS SEGMENT ACCOUNTED FOR
LARGEST MARKET SHARE IN 2021
4.3 STEM CELL ASSAYS MARKET SHARE, BY TYPE, 2022 VS. 2027
FIGURE 17 VIABILITY/CYTOTOXICITY ASSAYS SEGMENT WILL CONTINUE
TO DOMINATE MARKET IN 2027
4.4 STEM CELL ASSAYS MARKET SHARE, BY APPLICATION, 2021
FIGURE 18 REGENERATIVE MEDICINE & THERAPY DEVELOPMENT SEGMENT
DOMINATED MARKET IN 2021
4.5 STEM CELL ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE
FROM 2022 TO 2027
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 STEM CELL ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 STEM CELL ASSAYS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Increasing awareness about therapeutic potency of stem cells
5.2.1.2 Increasing funding for stem cell research
5.2.1.3 Rising demand for cell-based assays in drug discovery
5.2.1.4 Collaborations and agreements among market players for stem cell assay products & services
5.2.1.5 Rising incidence of cancer
TABLE 2 GLOBAL CANCER INCIDENCE, 2020 VS. 2040
5.2.2 RESTRAINTS
5.2.2.1 Issues in embryonic stem cell research
5.2.2.2 High cost of stem cell analysis instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging economies
5.2.3.2 Government initiatives to boost stem cell research
5.2.4 CHALLENGES
5.2.4.1 Lack of infrastructure for stem cell research in emerging economies
5.2.4.2 Dearth of trained and skilled professionals
5.3 RANGES/SCENARIOS
FIGURE 21 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF STEM CELL ASSAYS MARKET
5.4 IMPACT OF COVID-19 ON STEM CELL ASSAYS MARKET
5.4.1 INTRODUCTION
5.4.2 RESEARCH & DEVELOPMENT
5.4.3 RESEARCH FUNDING
5.4.4 SUPPLY CHAIN
FIGURE 22 STEM CELL ASSAYS MARKET SCENARIO WITH AND WITHOUT
COVID-19 IMPACT, 2019-2021
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR
STEM CELL ASSAY PRODUCT PROVIDERS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS
TABLE 3 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (TOP 5)
5.6.2 AVERAGE SELLING PRICE TREND
5.7 TECHNOLOGY ANALYSIS
5.7.1 MICROFABRICATION-ASSISTED TECHNOLOGIES
5.7.1.1 Microfluidics-based cell trap technology
5.7.1.2 Droplet-based microfluidic technology
5.7.1.3 Microwell-based analysis systems
5.7.2 ADVANCED TECHNOLOGIES
5.7.2.1 Bead-based multiplex assays
5.8 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS OF STEM CELL ASSAYS MARKET
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 25 STEM CELL ASSAYS MARKET: SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS
FIGURE 26 ECOSYSTEM ANALYSIS: STEM CELL ASSAYS MARKET
TABLE 4 SUPPLY CHAIN ECOSYSTEM
5.11 PATENT ANALYSIS
FIGURE 27 PATENT APPLICATIONS RELATED TO STEM CELL ASSAYS MARKET, JANUARY 2012–MARCH 2022
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 5 STEM CELL ASSAYS MARKET: LIST OF CONFERENCES AND EVENTS
5.13 REGULATORY ANALYSIS
5.13.1 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES
5.13.2 REGULATORY ANALYSIS FOR STEM CELL RESEARCH
5.13.2.1 US
5.13.2.2 EUROPE
5.13.2.2.1 Germany
5.13.2.2.2 UK
5.13.2.2.3 France
5.13.2.2.4 Italy
5.13.2.2.5 Spain
5.13.2.2.6 Switzerland
5.13.3 REGULATORY ANALYSIS FOR STEM CELL THERAPY
5.13.3.1 US
5.13.3.2 European Union
5.14 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 STEM CELL ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.14.1 THREAT OF NEW ENTRANTS
5.14.2 THREAT OF SUBSTITUTES
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 BARGAINING POWER OF SUPPLIERS
5.14.5 DEGREE OF COMPETITION
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES
AND THEIR INFLUENCE IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS IN PHARMACEUTICAL
COMPANIES IN BUYING PROCESS OF STEM CELL ASSAY PRODUCTS
5.15.2 KEY BUYING CRITERIA FOR STEM CELL ASSAY PRODUCTS
AMONG END USERS
FIGURE 29 KEY BUYING CRITERIA FOR END USERS
6 STEM CELL ASSAYS MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 7 STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2 VIABILITY/CYTOTOXICITY ASSAYS
TABLE 8 VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 9 NORTH AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 10 EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 11 ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 12 VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.1 TETRAZOLIUM REDUCTION ASSAYS
6.2.1.1 Growing use of tetrazolium reduction assays in high-throughput screening to drive segment growth
TABLE 13 TETRAZOLIUM REDUCTION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 14 NORTH AMERICA: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 EUROPE: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 ASIA PACIFIC: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 RESAZURIN CELL VIABILITY ASSAYS
6.2.2.1 Several advantages of resazurin cell viability assays to increase their adoption
TABLE 17 RESAZURIN CELL VIABILITY ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 18 NORTH AMERICA: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 EUROPE: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 ASIA PACIFIC: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 CALCEIN-AM CELL VIABILITY ASSAYS
6.2.3.1 Wide applications of Calcein-AM cell viability assays across various assay techniques to drive segment growth
TABLE 21 CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 22 NORTH AMERICA: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 EUROPE: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 ASIA PACIFIC: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.4 OTHER VIABILITY/CYTOTOXICITY ASSAYS
TABLE 25 OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 NORTH AMERICA: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 EUROPE: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 ASIA PACIFIC: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 ISOLATION & PURIFICATION ASSAYS
6.3.1 GROWING USE OF ISOLATION & PURIFICATION IN STEM CELL
ANALYSIS TO DRIVE SEGMENT GROWTH
TABLE 29 ISOLATION & PURIFICATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: ISOLATION & PURIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 31 EUROPE: ISOLATION & PURIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 ASIA PACIFIC: ISOLATION & PURIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 CELL IDENTIFICATION ASSAYS
6.4.1 CELL IDENTIFICATION ASSAYS IDENTIFY TARGET CELLS THROUGH MARKERS, BUFFERS, AND REAGENTS
TABLE 33 CELL IDENTIFICATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 NORTH AMERICA: CELL IDENTIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 EUROPE: CELL IDENTIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 ASIA PACIFIC: CELL IDENTIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 PROLIFERATION ASSAYS
6.5.1 CELL PROLIFERATION IS MEASURED ON THE BASIS OF
AVERAGE DNA CONTENT AND CELLULAR METABOLISM
TABLE 37 PROLIFERATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: PROLIFERATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 39 EUROPE: PROLIFERATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 ASIA PACIFIC: PROLIFERATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6 DIFFERENTIATION ASSAYS
6.6.1 AVAILABILITY OF VARIOUS STEM CELL DIFFERENTIAL ASSAY KITS TO BOOST SEGMENT GROWTH
TABLE 41 DIFFERENTIATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 42 NORTH AMERICA: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 EUROPE: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 ASIA PACIFIC: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.7 FUNCTION ASSAYS
6.7.1 RISING DEMAND FOR FUNCTION ASSAYS IN DRUG DISCOVERY TO DRIVE SEGMENT GROWTH
TABLE 45 FUNCTION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 46 NORTH AMERICA: FUNCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 EUROPE: FUNCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 ASIA PACIFIC: FUNCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8 APOPTOSIS ASSAYS
TABLE 49 APOPTOSIS ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 50 NORTH AMERICA: APOPTOSIS ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 51 EUROPE: APOPTOSIS ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 52 ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.8.1 CASPASE ASSAYS
6.8.1.1 Advantages offered by caspase assays to drive segment growth
TABLE 54 CASPASE ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: CASPASE ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 EUROPE: CASPASE ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 ASIA PACIFIC: CASPASE ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.2 ANNEXIN V & CELL PERMEABILITY ASSAYS
6.8.2.1 Increasing use of annexin V and cell permeability assays to drive segment growth
TABLE 58 ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 59 NORTH AMERICA: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 60 EUROPE: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 ASIA PACIFIC: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.3 DNA FRAGMENTATION ASSAYS
6.8.3.1 DNA fragmentation assays are used to study the
later stages of apoptosis
TABLE 62 DNA FRAGMENTATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 63 NORTH AMERICA: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 EUROPE: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 65 ASIA PACIFIC: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.4 MITOCHONDRIAL ASSAYS
6.8.4.1 Mitochondrial assays are widely used to detect mitochondrial changes associated with apoptosis
TABLE 66 MITOCHONDRIAL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 EUROPE: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 ASIA PACIFIC: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 STEM CELL ASSAYS MARKET, BY CELL TYPE
7.1 INTRODUCTION
TABLE 70 STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
7.2 ADULT STEM CELLS
TABLE 71 ADULT STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 ADULT STEM CELLS ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 73 NORTH AMERICA: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 ASIA PACIFIC: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 MESENCHYMAL STEM CELLS
7.2.1.1 Increasing adoption of MSCs as potential treatment for various conditions to drive market growth
TABLE 76 MESENCHYMAL STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 77 NORTH AMERICA: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 78 EUROPE: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 ASIA PACIFIC: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 INDUCED PLURIPOTENT STEM CELLS
7.2.2.1 Increased adoption of iPSCs in research on cell therapies & regenerative medicine to support market growth
TABLE 80 INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 81 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 HEMATOPOIETIC STEM CELLS
7.2.3.1 Increasing focus on developing HSC-based therapies to
drive market growth
TABLE 84 HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 85 NORTH AMERICA: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 86 EUROPE: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 ASIA PACIFIC: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.4 UMBILICAL CORD STEM CELLS
7.2.4.1 Rising investments and collaborations for developing umbilical cord stem cell therapies to propel market growth
TABLE 88 UMBILICAL CORD STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 89 NORTH AMERICA: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 90 EUROPE: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 ASIA PACIFIC: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.5 NEURAL STEM CELLS
7.2.5.1 Increasing research to evaluate the potency of NSCs in disease treatment will drive segment growth
TABLE 92 NEURAL STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 93 NORTH AMERICA: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 EUROPE: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 ASIA PACIFIC: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 HUMAN EMBRYONIC STEM CELLS
7.3.1 ESCS CAN BE STORED AND PROCESSED EASILY
TABLE 96 HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 97 NORTH AMERICA: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 EUROPE: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 99 ASIA PACIFIC: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE
8.1 INTRODUCTION
TABLE 100 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
8.2 INSTRUMENTS
TABLE 101 STEM CELL ASSAY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 105 STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2.1 FLOW CYTOMETERS
8.2.1.1 Technological advancements in flow cytometry
to drive segment growth
TABLE 106 FLOW CYTOMETERS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 107 NORTH AMERICA: FLOW CYTOMETERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 108 EUROPE: FLOW CYTOMETERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 109 ASIA PACIFIC: FLOW CYTOMETERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.2 CELL IMAGING & ANALYSIS SYSTEMS
8.2.2.1 High demand for cell imaging and analysis in cell behavior research studies to support segment growth
TABLE 110 CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 111 NORTH AMERICA: CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 112 EUROPE: CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 113 ASIA PACIFIC: CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.3 MICROELECTRODE ARRAYS
8.2.3.1 Increasing use of microelectrode arrays in stem cell research
to drive segment growth
TABLE 114 MICROELECTRODE ARRAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 115 NORTH AMERICA: MICROELECTRODE ARRAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 116 EUROPE: MICROELECTRODE ARRAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 117 ASIA PACIFIC: MICROELECTRODE ARRAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.4 AUTOMATED CELL COUNTERS
8.2.4.1 Increasing adoption of automated cell counters to
drive segment growth
TABLE 118 AUTOMATED CELL COUNTERS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 119 NORTH AMERICA: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 120 EUROPE: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 121 ASIA PACIFIC: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 KITS
8.3.1 RAPID EVOLUTION OF ASSAY PLATFORMS AND EMERGENCE OF NEW TECHNOLOGY PLATFORMS TO DRIVE SEGMENT GROWTH
TABLE 122 STEM CELL ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 123 NORTH AMERICA: STEM CELL ASSAY KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 124 EUROPE: STEM CELL ASSAY KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 125 ASIA PACIFIC: STEM CELL ASSAY KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 SERVICES
8.4.1 RISING DEMAND FOR ASSAY DEVELOPMENT SERVICES TO
DRIVE SEGMENT GROWTH
TABLE 126 STEM CELL ASSAY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 127 NORTH AMERICA: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 128 EUROPE: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 129 ASIA PACIFIC: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
9 STEM CELL ASSAYS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 130 STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2 REGENERATIVE MEDICINE & THERAPY DEVELOPMENT
TABLE 131 STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 132 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 133 EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 134 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 135 STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
9.2.1 ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS
9.2.1.1 Increasing prevalence of orthopedic disorders to
drive segment growth
TABLE 136 STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 137 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 138 EUROPE: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 139 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.2 DERMATOLOGY APPLICATIONS
9.2.2.1 Increasing use of stem cells in skin disease treatment to drive segment growth
TABLE 140 STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 141 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 142 EUROPE: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 143 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.3 CARDIOVASCULAR APPLICATIONS
9.2.3.1 Growing demand for effective cardiovascular disease treatments and rising number of R&D activities to drive segment growth
TABLE 144 STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 145 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 146 EUROPE: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 147 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.4 CENTRAL NERVOUS SYSTEM APPLICATIONS
9.2.4.1 Promising stem cell therapies for degenerative neurological disorders to drive segment growth
TABLE 148 STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 149 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 150 EUROPE: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 151 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.5 ONCOLOGY APPLICATIONS
9.2.5.1 Increasing prevalence of cancer to drive segment growth
TABLE 152 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 153 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015–2035
TABLE 154 STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 155 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 156 EUROPE: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 157 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.6 DIABETES APPLICATIONS
9.2.6.1 Rising incidence of diabetes to drive segment growth
TABLE 158 TOP FIVE COUNTRIES WITH THE HIGHEST NUMBER OF
DIABETICS (20–79 YEARS), 2021 VS. 2045
TABLE 159 STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 160 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 161 EUROPE: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 162 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.7 OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS
TABLE 163 STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 164 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 165 EUROPE: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE
MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 166 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 DRUG DISCOVERY & DEVELOPMENT
9.3.1 RECENT PROGRESS IN THE DEVELOPMENT OF STEM CELL ASSAYS
TO DRIVE SEGMENT GROWTH
TABLE 167 STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 168 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 169 EUROPE: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 170 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 CLINICAL RESEARCH
9.4.1 INCREASING NUMBER OF PROMISING CLINICAL TRIALS USING
STEM CELLS TO BOOST SEGMENT GROWTH
TABLE 171 STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY REGION, 2020–2027 (USD MILLION)
TABLE 172 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 173 EUROPE: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 174 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
10 STEM CELL ASSAYS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 175 STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE LARGEST END USERS OF STEM CELL ASSAYS
TABLE 176 STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 177 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 178 EUROPE: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 179 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 NEW STEM CELL RESEARCH INSTITUTES ARE BEING ESTABLISHED FOR STEM CELL RESEARCH AND REGENERATIVE MEDICINE
TABLE 180 STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 181 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 182 EUROPE: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 183 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
11 STEM CELL ASSAYS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 184 STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: STEM CELL ASSAYS MARKET SNAPSHOT
TABLE 185 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 186 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 NORTH AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 188 NORTH AMERICA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 189 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 190 NORTH AMERICA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 191 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 192 NORTH AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 193 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 194 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 195 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 Rising funding for stem cell research to drive market growth
TABLE 196 US: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 197 US: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 198 US: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 199 US: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 200 US: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 201 US: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 202 US: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 203 US: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 204 US: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 205 US: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Rising government investments & funding to drive market in Canada
TABLE 206 CANADA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 207 CANADA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 208 CANADA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 209 CANADA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 210 CANADA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 211 CANADA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 212 CANADA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 213 CANADA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 214 CANADA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 215 CANADA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 216 EUROPE: STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 217 EUROPE: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 218 EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 219 EUROPE: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 220 EUROPE: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 221 EUROPE: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 222 EUROPE: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 223 EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 224 EUROPE: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 225 EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 226 EUROPE: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Growing biopharma industry and focus on regenerative medicine to drive market growth
TABLE 227 GERMANY: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 228 GERMANY: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 229 GERMANY: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 230 GERMANY: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 231 GERMANY: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 232 GERMANY: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 233 GERMANY: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 234 GERMANY: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 235 GERMANY: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 236 GERMANY: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.2 UK
11.3.2.1 Focus on innovation will increase demand for stem cell-based therapeutics
TABLE 237 UK: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 238 UK: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 239 UK: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 240 UK: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 241 UK: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 242 UK: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 243 UK: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 244 UK: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 245 UK: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 246 UK: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Government initiatives to support market growth in France
TABLE 247 FRANCE: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 248 FRANCE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 249 FRANCE: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 250 FRANCE: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 251 FRANCE: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 252 FRANCE: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 253 FRANCE: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 254 FRANCE: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 255 FRANCE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 256 FRANCE: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Investment in R&D for development of new therapeutics to boost stem cell assays market
TABLE 257 ITALY: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 258 ITALY: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 259 ITALY: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 260 ITALY: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 261 ITALY: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 262 ITALY: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 263 ITALY: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 264 ITALY: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 265 ITALY: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 266 ITALY: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing investments from private and public organizations to drive market growth
TABLE 267 SPAIN: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 268 SPAIN: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 269 SPAIN: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 270 SPAIN: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 271 SPAIN: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 272 SPAIN: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 273 SPAIN: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 274 SPAIN: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 275 SPAIN: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 276 SPAIN: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.6 SWITZERLAND
11.3.6.1 Growing life science research to drive market growth
TABLE 277 SWITZERLAND: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 278 SWITZERLAND: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279 SWITZERLAND: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 280 SWITZERLAND: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 281 SWITZERLAND: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 282 SWITZERLAND: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 283 SWITZERLAND: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 284 SWITZERLAND: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 285 SWITZERLAND: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 286 SWITZERLAND: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 287 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 288 REST OF EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 289 REST OF EUROPE: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 290 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 291 REST OF EUROPE: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 292 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 293 REST OF EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 294 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 295 REST OF EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 296 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: STEM CELL ASSAYS MARKET SNAPSHOT
TABLE 297 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 298 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 299 ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 300 ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 301 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 302 ASIA PACIFIC: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 303 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 304 ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 305 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 306 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 307 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Growing focus on stem cell research to drive market growth in China
TABLE 308 CHINA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 309 CHINA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 310 CHINA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 311 CHINA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 312 CHINA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 313 CHINA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 314 CHINA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 315 CHINA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 316 CHINA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 317 CHINA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Growing collaborations for stem cell research to drive market growth in the country
TABLE 318 JAPAN: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 319 JAPAN: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 320 JAPAN: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 321 JAPAN: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 322 JAPAN: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 323 JAPAN: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 324 JAPAN: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 325 JAPAN: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 326 JAPAN: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 327 JAPAN: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Government initiatives supporting stem cell research to drive market growth in India
TABLE 328 INDIA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 329 INDIA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 330 INDIA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 331 INDIA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 332 INDIA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 333 INDIA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 334 INDIA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 335 INDIA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 336 INDIA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 337 INDIA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 338 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 339 REST OF ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 340 REST OF ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 341 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 342 REST OF ASIA PACIFIC: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 343 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 344 REST OF ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 345 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 346 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 347 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 GROWTH OF BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH IN LATIN AMERICA
TABLE 348 MEXICO: CANCER CASES, BY CANCER TYPE, 2020
TABLE 349 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 350 LATIN AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 351 LATIN AMERICA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 352 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 353 LATIN AMERICA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 354 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 355 LATIN AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 356 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 357 LATIN AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 358 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 INCREASING COLLABORATIONS FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH IN MEA
TABLE 359 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 360 MIDDLE EAST & AFRICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 361 MIDDLE EAST & AFRICA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 362 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 363 MIDDLE EAST & AFRICA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 364 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 365 MIDDLE EAST & AFRICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 366 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 367 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 368 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 32 STEM CELL ASSAYS MARKET: STRATEGIES ADOPTED
12.3 MARKET SHARE ANALYSIS
FIGURE 33 STEM CELL ASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
TABLE 369 STEM CELL ASSAYS MARKET: DEGREE OF COMPETITION
12.4 REVENUE ANALYSIS
FIGURE 34 REVENUE ANALYSIS FOR KEY COMPANIES (2019-2021)
12.5 COMPANY EVALUATION QUADRANT
FIGURE 35 STEM CELL ASSAYS MARKET: COMPANY EVALUATION MATRIX, 2021
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
12.6.1 OVERALL FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 370 PRODUCT & REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN
STEM CELL ASSAYS MARKET
12.6.2 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 371 PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN
STEM CELL ASSAYS MARKET
12.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 372 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN
STEM CELL ASSAYS MARKET
12.7 COMPANY EVALUATION QUADRANT: STARTUPS/SMES
FIGURE 36 STEM CELL ASSAYS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2021
12.7.1 PROGRESSIVE COMPANIES
12.7.2 STARTING BLOCKS
12.7.3 RESPONSIVE COMPANIES
12.7.4 DYNAMIC COMPANIES
12.7.4.1 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 373 STEM CELL ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 374 STEM CELL ASSAYS MARKET: COMPETITIVE BENCHMARKING
OF KEY PLAYERS (STARTUPS/SMES)
12.8 COMPETITIVE SCENARIO AND TRENDS
12.8.1 PRODUCT LAUNCHES
TABLE 375 STEM CELL ASSAYS MARKET: PRODUCT LAUNCHES, JANUARY 2018-MAY 2022
12.8.2 DEALS
TABLE 376 STEM CELL ASSAYS MARKET: DEALS, JANUARY 2018-MAY 2022
12.8.3 OTHER DEVELOPMENTS
TABLE 377 STEM CELL ASSAYS MARKET: OTHER DEVELOPMENTS, JANUARY 2018-MAY 2022
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 THERMO FISHER SCIENTIFIC INC.
TABLE 378 THERMO FISHER SCIENTIFIC INC: BUSINESS OVERVIEW
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
13.1.2 MERK KGAA
TABLE 379 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2021)
13.1.3 DANAHER
TABLE 380 DANAHER: BUSINESS OVERVIEW
FIGURE 39 DANAHER: COMPANY SNAPSHOT (2021)
13.1.4 BECTON, DICKINSON AND COMPANY
TABLE 381 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 40 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
13.1.5 BIO-RAD LABORATORIES
TABLE 382 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 41 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.6 PERKINELMER INC.
TABLE 383 PERKINELMER INC.: BUSINESS OVERVIEW
FIGURE 42 PERKINELMER INC.: COMPANY SNAPSHOT (2021)
13.1.7 AGILENT TECHNOLOGIES, INC.
TABLE 384 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
13.1.8 BIO-TECHNE CORPORATION
TABLE 385 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
FIGURE 44 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2020)
13.1.9 FUJIFILM HOLDINGS CORPORATION
TABLE 386 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
13.1.10 CHARLES RIVER LABORATORIES
TABLE 387 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.11 LONZA GROUP
TABLE 388 LONZA GROUP: BUSINESS OVERVIEW
FIGURE 47 LONZA GROUP: COMPANY SNAPSHOT (2021)
13.1.12 PROMEGA CORPORATION
TABLE 389 PROMEGA CORPORATION: BUSINESS OVERVIEW
13.1.13 MILTENYI BIOTEC
TABLE 390 MILTENYI BIOTEC: BUSINESS OVERVIEW
13.1.14 STEMCELL TECHNOLOGIES
TABLE 391 STEMCELL TECHNOLOGIES: BUSINESS OVERVIEW
13.1.15 HEMOGENIX INC.
TABLE 392 HEMOGENIX INC.: BUSINESS OVERVIEW
13.1.16 CELL BIOLABS, INC.
TABLE 393 CELL BIOLABS, INC.: BUSINESS OVERVIEW
13.2 OTHER COMPANIES
13.2.1 TAKARA BIO INC.
13.2.2 CREATIVE BIOARRAY
13.2.3 AAT BIOQUEST, INC.
13.2.4 ABCAM PLC
13.2.5 BPS BIOSCIENCE, INC.
13.2.6 ENZO BIOCHEM INC.
13.2.7 PROMOCELL GMBH
13.2.8 BIOTIUM
13.2.9 GENO TECHNOLOGY INC.
13.2.10 REACHBIO RESEARCH LABS
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES, BY RESPONDENT, DESIGNATION, AND REGION
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 STEM CELL ASSAYS MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2021
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 6 STEM CELL ASSAYS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 7 STEM CELL ASSAYS MARKET (DEMAND SIDE):
GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
2.3.1 DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.4.1 COVID-19 ASSUMPTIONS
2.5 RISK ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 9 STEM CELL ASSAYS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 STEM CELL ASSAYS MARKET, BY CELL TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 11 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 12 STEM CELL ASSAYS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 13 STEM CELL ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF STEM CELL ASSAYS MARKET
4 PREMIUM INSIGHTS
4.1 STEM CELL ASSAYS MARKET OVERVIEW
FIGURE 15 RISING AWARENESS ABOUT THERAPEUTIC POTENCY OF
STEM CELLS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2021)
FIGURE 16 INSTRUMENTS SEGMENT ACCOUNTED FOR
LARGEST MARKET SHARE IN 2021
4.3 STEM CELL ASSAYS MARKET SHARE, BY TYPE, 2022 VS. 2027
FIGURE 17 VIABILITY/CYTOTOXICITY ASSAYS SEGMENT WILL CONTINUE
TO DOMINATE MARKET IN 2027
4.4 STEM CELL ASSAYS MARKET SHARE, BY APPLICATION, 2021
FIGURE 18 REGENERATIVE MEDICINE & THERAPY DEVELOPMENT SEGMENT
DOMINATED MARKET IN 2021
4.5 STEM CELL ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE
FROM 2022 TO 2027
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 STEM CELL ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 STEM CELL ASSAYS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Increasing awareness about therapeutic potency of stem cells
5.2.1.2 Increasing funding for stem cell research
5.2.1.3 Rising demand for cell-based assays in drug discovery
5.2.1.4 Collaborations and agreements among market players for stem cell assay products & services
5.2.1.5 Rising incidence of cancer
TABLE 2 GLOBAL CANCER INCIDENCE, 2020 VS. 2040
5.2.2 RESTRAINTS
5.2.2.1 Issues in embryonic stem cell research
5.2.2.2 High cost of stem cell analysis instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging economies
5.2.3.2 Government initiatives to boost stem cell research
5.2.4 CHALLENGES
5.2.4.1 Lack of infrastructure for stem cell research in emerging economies
5.2.4.2 Dearth of trained and skilled professionals
5.3 RANGES/SCENARIOS
FIGURE 21 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF STEM CELL ASSAYS MARKET
5.4 IMPACT OF COVID-19 ON STEM CELL ASSAYS MARKET
5.4.1 INTRODUCTION
5.4.2 RESEARCH & DEVELOPMENT
5.4.3 RESEARCH FUNDING
5.4.4 SUPPLY CHAIN
FIGURE 22 STEM CELL ASSAYS MARKET SCENARIO WITH AND WITHOUT
COVID-19 IMPACT, 2019-2021
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR
STEM CELL ASSAY PRODUCT PROVIDERS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS
TABLE 3 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (TOP 5)
5.6.2 AVERAGE SELLING PRICE TREND
5.7 TECHNOLOGY ANALYSIS
5.7.1 MICROFABRICATION-ASSISTED TECHNOLOGIES
5.7.1.1 Microfluidics-based cell trap technology
5.7.1.2 Droplet-based microfluidic technology
5.7.1.3 Microwell-based analysis systems
5.7.2 ADVANCED TECHNOLOGIES
5.7.2.1 Bead-based multiplex assays
5.8 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS OF STEM CELL ASSAYS MARKET
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 25 STEM CELL ASSAYS MARKET: SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS
FIGURE 26 ECOSYSTEM ANALYSIS: STEM CELL ASSAYS MARKET
TABLE 4 SUPPLY CHAIN ECOSYSTEM
5.11 PATENT ANALYSIS
FIGURE 27 PATENT APPLICATIONS RELATED TO STEM CELL ASSAYS MARKET, JANUARY 2012–MARCH 2022
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 5 STEM CELL ASSAYS MARKET: LIST OF CONFERENCES AND EVENTS
5.13 REGULATORY ANALYSIS
5.13.1 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES
5.13.2 REGULATORY ANALYSIS FOR STEM CELL RESEARCH
5.13.2.1 US
5.13.2.2 EUROPE
5.13.2.2.1 Germany
5.13.2.2.2 UK
5.13.2.2.3 France
5.13.2.2.4 Italy
5.13.2.2.5 Spain
5.13.2.2.6 Switzerland
5.13.3 REGULATORY ANALYSIS FOR STEM CELL THERAPY
5.13.3.1 US
5.13.3.2 European Union
5.14 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 STEM CELL ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.14.1 THREAT OF NEW ENTRANTS
5.14.2 THREAT OF SUBSTITUTES
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 BARGAINING POWER OF SUPPLIERS
5.14.5 DEGREE OF COMPETITION
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES
AND THEIR INFLUENCE IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS IN PHARMACEUTICAL
COMPANIES IN BUYING PROCESS OF STEM CELL ASSAY PRODUCTS
5.15.2 KEY BUYING CRITERIA FOR STEM CELL ASSAY PRODUCTS
AMONG END USERS
FIGURE 29 KEY BUYING CRITERIA FOR END USERS
6 STEM CELL ASSAYS MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 7 STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2 VIABILITY/CYTOTOXICITY ASSAYS
TABLE 8 VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 9 NORTH AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 10 EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 11 ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 12 VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.1 TETRAZOLIUM REDUCTION ASSAYS
6.2.1.1 Growing use of tetrazolium reduction assays in high-throughput screening to drive segment growth
TABLE 13 TETRAZOLIUM REDUCTION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 14 NORTH AMERICA: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 EUROPE: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 ASIA PACIFIC: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 RESAZURIN CELL VIABILITY ASSAYS
6.2.2.1 Several advantages of resazurin cell viability assays to increase their adoption
TABLE 17 RESAZURIN CELL VIABILITY ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 18 NORTH AMERICA: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 EUROPE: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 ASIA PACIFIC: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 CALCEIN-AM CELL VIABILITY ASSAYS
6.2.3.1 Wide applications of Calcein-AM cell viability assays across various assay techniques to drive segment growth
TABLE 21 CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 22 NORTH AMERICA: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 EUROPE: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 ASIA PACIFIC: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.4 OTHER VIABILITY/CYTOTOXICITY ASSAYS
TABLE 25 OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 NORTH AMERICA: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 EUROPE: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 ASIA PACIFIC: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 ISOLATION & PURIFICATION ASSAYS
6.3.1 GROWING USE OF ISOLATION & PURIFICATION IN STEM CELL
ANALYSIS TO DRIVE SEGMENT GROWTH
TABLE 29 ISOLATION & PURIFICATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: ISOLATION & PURIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 31 EUROPE: ISOLATION & PURIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 ASIA PACIFIC: ISOLATION & PURIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 CELL IDENTIFICATION ASSAYS
6.4.1 CELL IDENTIFICATION ASSAYS IDENTIFY TARGET CELLS THROUGH MARKERS, BUFFERS, AND REAGENTS
TABLE 33 CELL IDENTIFICATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 NORTH AMERICA: CELL IDENTIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 EUROPE: CELL IDENTIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 ASIA PACIFIC: CELL IDENTIFICATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 PROLIFERATION ASSAYS
6.5.1 CELL PROLIFERATION IS MEASURED ON THE BASIS OF
AVERAGE DNA CONTENT AND CELLULAR METABOLISM
TABLE 37 PROLIFERATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: PROLIFERATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 39 EUROPE: PROLIFERATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 ASIA PACIFIC: PROLIFERATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6 DIFFERENTIATION ASSAYS
6.6.1 AVAILABILITY OF VARIOUS STEM CELL DIFFERENTIAL ASSAY KITS TO BOOST SEGMENT GROWTH
TABLE 41 DIFFERENTIATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 42 NORTH AMERICA: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 EUROPE: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 ASIA PACIFIC: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.7 FUNCTION ASSAYS
6.7.1 RISING DEMAND FOR FUNCTION ASSAYS IN DRUG DISCOVERY TO DRIVE SEGMENT GROWTH
TABLE 45 FUNCTION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 46 NORTH AMERICA: FUNCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 EUROPE: FUNCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 ASIA PACIFIC: FUNCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8 APOPTOSIS ASSAYS
TABLE 49 APOPTOSIS ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 50 NORTH AMERICA: APOPTOSIS ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 51 EUROPE: APOPTOSIS ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 52 ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.8.1 CASPASE ASSAYS
6.8.1.1 Advantages offered by caspase assays to drive segment growth
TABLE 54 CASPASE ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: CASPASE ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 EUROPE: CASPASE ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 ASIA PACIFIC: CASPASE ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.2 ANNEXIN V & CELL PERMEABILITY ASSAYS
6.8.2.1 Increasing use of annexin V and cell permeability assays to drive segment growth
TABLE 58 ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 59 NORTH AMERICA: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 60 EUROPE: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 ASIA PACIFIC: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.3 DNA FRAGMENTATION ASSAYS
6.8.3.1 DNA fragmentation assays are used to study the
later stages of apoptosis
TABLE 62 DNA FRAGMENTATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 63 NORTH AMERICA: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 EUROPE: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 65 ASIA PACIFIC: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.4 MITOCHONDRIAL ASSAYS
6.8.4.1 Mitochondrial assays are widely used to detect mitochondrial changes associated with apoptosis
TABLE 66 MITOCHONDRIAL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 EUROPE: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 ASIA PACIFIC: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 STEM CELL ASSAYS MARKET, BY CELL TYPE
7.1 INTRODUCTION
TABLE 70 STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
7.2 ADULT STEM CELLS
TABLE 71 ADULT STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 ADULT STEM CELLS ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 73 NORTH AMERICA: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 ASIA PACIFIC: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 MESENCHYMAL STEM CELLS
7.2.1.1 Increasing adoption of MSCs as potential treatment for various conditions to drive market growth
TABLE 76 MESENCHYMAL STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 77 NORTH AMERICA: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 78 EUROPE: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 ASIA PACIFIC: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 INDUCED PLURIPOTENT STEM CELLS
7.2.2.1 Increased adoption of iPSCs in research on cell therapies & regenerative medicine to support market growth
TABLE 80 INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 81 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 HEMATOPOIETIC STEM CELLS
7.2.3.1 Increasing focus on developing HSC-based therapies to
drive market growth
TABLE 84 HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 85 NORTH AMERICA: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 86 EUROPE: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 ASIA PACIFIC: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.4 UMBILICAL CORD STEM CELLS
7.2.4.1 Rising investments and collaborations for developing umbilical cord stem cell therapies to propel market growth
TABLE 88 UMBILICAL CORD STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 89 NORTH AMERICA: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 90 EUROPE: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 ASIA PACIFIC: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.5 NEURAL STEM CELLS
7.2.5.1 Increasing research to evaluate the potency of NSCs in disease treatment will drive segment growth
TABLE 92 NEURAL STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 93 NORTH AMERICA: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 EUROPE: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 ASIA PACIFIC: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 HUMAN EMBRYONIC STEM CELLS
7.3.1 ESCS CAN BE STORED AND PROCESSED EASILY
TABLE 96 HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 97 NORTH AMERICA: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 EUROPE: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 99 ASIA PACIFIC: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE
8.1 INTRODUCTION
TABLE 100 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
8.2 INSTRUMENTS
TABLE 101 STEM CELL ASSAY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 105 STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2.1 FLOW CYTOMETERS
8.2.1.1 Technological advancements in flow cytometry
to drive segment growth
TABLE 106 FLOW CYTOMETERS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 107 NORTH AMERICA: FLOW CYTOMETERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 108 EUROPE: FLOW CYTOMETERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 109 ASIA PACIFIC: FLOW CYTOMETERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.2 CELL IMAGING & ANALYSIS SYSTEMS
8.2.2.1 High demand for cell imaging and analysis in cell behavior research studies to support segment growth
TABLE 110 CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 111 NORTH AMERICA: CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 112 EUROPE: CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 113 ASIA PACIFIC: CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.3 MICROELECTRODE ARRAYS
8.2.3.1 Increasing use of microelectrode arrays in stem cell research
to drive segment growth
TABLE 114 MICROELECTRODE ARRAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 115 NORTH AMERICA: MICROELECTRODE ARRAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 116 EUROPE: MICROELECTRODE ARRAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 117 ASIA PACIFIC: MICROELECTRODE ARRAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.4 AUTOMATED CELL COUNTERS
8.2.4.1 Increasing adoption of automated cell counters to
drive segment growth
TABLE 118 AUTOMATED CELL COUNTERS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 119 NORTH AMERICA: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 120 EUROPE: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 121 ASIA PACIFIC: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 KITS
8.3.1 RAPID EVOLUTION OF ASSAY PLATFORMS AND EMERGENCE OF NEW TECHNOLOGY PLATFORMS TO DRIVE SEGMENT GROWTH
TABLE 122 STEM CELL ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 123 NORTH AMERICA: STEM CELL ASSAY KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 124 EUROPE: STEM CELL ASSAY KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 125 ASIA PACIFIC: STEM CELL ASSAY KITS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 SERVICES
8.4.1 RISING DEMAND FOR ASSAY DEVELOPMENT SERVICES TO
DRIVE SEGMENT GROWTH
TABLE 126 STEM CELL ASSAY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 127 NORTH AMERICA: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 128 EUROPE: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 129 ASIA PACIFIC: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
9 STEM CELL ASSAYS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 130 STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2 REGENERATIVE MEDICINE & THERAPY DEVELOPMENT
TABLE 131 STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 132 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 133 EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 134 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 135 STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
9.2.1 ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS
9.2.1.1 Increasing prevalence of orthopedic disorders to
drive segment growth
TABLE 136 STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 137 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 138 EUROPE: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 139 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.2 DERMATOLOGY APPLICATIONS
9.2.2.1 Increasing use of stem cells in skin disease treatment to drive segment growth
TABLE 140 STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 141 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 142 EUROPE: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 143 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.3 CARDIOVASCULAR APPLICATIONS
9.2.3.1 Growing demand for effective cardiovascular disease treatments and rising number of R&D activities to drive segment growth
TABLE 144 STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 145 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 146 EUROPE: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 147 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.4 CENTRAL NERVOUS SYSTEM APPLICATIONS
9.2.4.1 Promising stem cell therapies for degenerative neurological disorders to drive segment growth
TABLE 148 STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 149 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 150 EUROPE: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 151 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.5 ONCOLOGY APPLICATIONS
9.2.5.1 Increasing prevalence of cancer to drive segment growth
TABLE 152 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 153 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015–2035
TABLE 154 STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 155 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 156 EUROPE: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 157 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.6 DIABETES APPLICATIONS
9.2.6.1 Rising incidence of diabetes to drive segment growth
TABLE 158 TOP FIVE COUNTRIES WITH THE HIGHEST NUMBER OF
DIABETICS (20–79 YEARS), 2021 VS. 2045
TABLE 159 STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 160 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 161 EUROPE: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 162 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.7 OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS
TABLE 163 STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 164 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 165 EUROPE: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE
MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 166 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 DRUG DISCOVERY & DEVELOPMENT
9.3.1 RECENT PROGRESS IN THE DEVELOPMENT OF STEM CELL ASSAYS
TO DRIVE SEGMENT GROWTH
TABLE 167 STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 168 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 169 EUROPE: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 170 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 CLINICAL RESEARCH
9.4.1 INCREASING NUMBER OF PROMISING CLINICAL TRIALS USING
STEM CELLS TO BOOST SEGMENT GROWTH
TABLE 171 STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY REGION, 2020–2027 (USD MILLION)
TABLE 172 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 173 EUROPE: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 174 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
10 STEM CELL ASSAYS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 175 STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE LARGEST END USERS OF STEM CELL ASSAYS
TABLE 176 STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 177 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 178 EUROPE: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 179 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 NEW STEM CELL RESEARCH INSTITUTES ARE BEING ESTABLISHED FOR STEM CELL RESEARCH AND REGENERATIVE MEDICINE
TABLE 180 STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 181 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 182 EUROPE: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 183 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
11 STEM CELL ASSAYS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 184 STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: STEM CELL ASSAYS MARKET SNAPSHOT
TABLE 185 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 186 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 NORTH AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 188 NORTH AMERICA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 189 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 190 NORTH AMERICA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 191 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 192 NORTH AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 193 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 194 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 195 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 Rising funding for stem cell research to drive market growth
TABLE 196 US: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 197 US: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 198 US: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 199 US: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 200 US: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 201 US: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 202 US: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 203 US: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 204 US: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 205 US: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Rising government investments & funding to drive market in Canada
TABLE 206 CANADA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 207 CANADA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 208 CANADA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 209 CANADA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 210 CANADA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 211 CANADA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 212 CANADA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 213 CANADA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 214 CANADA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 215 CANADA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 216 EUROPE: STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 217 EUROPE: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 218 EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 219 EUROPE: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 220 EUROPE: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 221 EUROPE: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 222 EUROPE: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 223 EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 224 EUROPE: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 225 EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 226 EUROPE: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Growing biopharma industry and focus on regenerative medicine to drive market growth
TABLE 227 GERMANY: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 228 GERMANY: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 229 GERMANY: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 230 GERMANY: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 231 GERMANY: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 232 GERMANY: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 233 GERMANY: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 234 GERMANY: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 235 GERMANY: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 236 GERMANY: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.2 UK
11.3.2.1 Focus on innovation will increase demand for stem cell-based therapeutics
TABLE 237 UK: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 238 UK: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 239 UK: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 240 UK: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 241 UK: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 242 UK: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 243 UK: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 244 UK: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 245 UK: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 246 UK: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Government initiatives to support market growth in France
TABLE 247 FRANCE: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 248 FRANCE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 249 FRANCE: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 250 FRANCE: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 251 FRANCE: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 252 FRANCE: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 253 FRANCE: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 254 FRANCE: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 255 FRANCE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 256 FRANCE: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Investment in R&D for development of new therapeutics to boost stem cell assays market
TABLE 257 ITALY: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 258 ITALY: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 259 ITALY: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 260 ITALY: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 261 ITALY: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 262 ITALY: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 263 ITALY: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 264 ITALY: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 265 ITALY: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 266 ITALY: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing investments from private and public organizations to drive market growth
TABLE 267 SPAIN: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 268 SPAIN: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 269 SPAIN: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 270 SPAIN: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 271 SPAIN: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 272 SPAIN: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 273 SPAIN: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 274 SPAIN: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 275 SPAIN: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 276 SPAIN: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.6 SWITZERLAND
11.3.6.1 Growing life science research to drive market growth
TABLE 277 SWITZERLAND: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 278 SWITZERLAND: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279 SWITZERLAND: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 280 SWITZERLAND: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 281 SWITZERLAND: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 282 SWITZERLAND: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 283 SWITZERLAND: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 284 SWITZERLAND: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 285 SWITZERLAND: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 286 SWITZERLAND: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 287 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 288 REST OF EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 289 REST OF EUROPE: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 290 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 291 REST OF EUROPE: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 292 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 293 REST OF EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 294 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 295 REST OF EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 296 REST OF EUROPE: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: STEM CELL ASSAYS MARKET SNAPSHOT
TABLE 297 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 298 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 299 ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 300 ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 301 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 302 ASIA PACIFIC: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 303 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 304 ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 305 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 306 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 307 ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Growing focus on stem cell research to drive market growth in China
TABLE 308 CHINA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 309 CHINA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 310 CHINA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 311 CHINA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 312 CHINA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 313 CHINA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 314 CHINA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 315 CHINA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 316 CHINA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 317 CHINA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Growing collaborations for stem cell research to drive market growth in the country
TABLE 318 JAPAN: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 319 JAPAN: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 320 JAPAN: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 321 JAPAN: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 322 JAPAN: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 323 JAPAN: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 324 JAPAN: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 325 JAPAN: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 326 JAPAN: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 327 JAPAN: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Government initiatives supporting stem cell research to drive market growth in India
TABLE 328 INDIA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 329 INDIA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 330 INDIA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 331 INDIA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 332 INDIA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 333 INDIA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 334 INDIA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 335 INDIA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 336 INDIA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 337 INDIA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 338 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 339 REST OF ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 340 REST OF ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 341 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 342 REST OF ASIA PACIFIC: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 343 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 344 REST OF ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 345 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 346 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 347 REST OF ASIA PACIFIC: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 GROWTH OF BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH IN LATIN AMERICA
TABLE 348 MEXICO: CANCER CASES, BY CANCER TYPE, 2020
TABLE 349 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 350 LATIN AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 351 LATIN AMERICA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 352 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 353 LATIN AMERICA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 354 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 355 LATIN AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 356 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 357 LATIN AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 358 LATIN AMERICA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 INCREASING COLLABORATIONS FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH IN MEA
TABLE 359 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 360 MIDDLE EAST & AFRICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 361 MIDDLE EAST & AFRICA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 362 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 363 MIDDLE EAST & AFRICA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 364 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 365 MIDDLE EAST & AFRICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 366 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 367 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 368 MIDDLE EAST & AFRICA: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 32 STEM CELL ASSAYS MARKET: STRATEGIES ADOPTED
12.3 MARKET SHARE ANALYSIS
FIGURE 33 STEM CELL ASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
TABLE 369 STEM CELL ASSAYS MARKET: DEGREE OF COMPETITION
12.4 REVENUE ANALYSIS
FIGURE 34 REVENUE ANALYSIS FOR KEY COMPANIES (2019-2021)
12.5 COMPANY EVALUATION QUADRANT
FIGURE 35 STEM CELL ASSAYS MARKET: COMPANY EVALUATION MATRIX, 2021
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
12.6.1 OVERALL FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 370 PRODUCT & REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN
STEM CELL ASSAYS MARKET
12.6.2 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 371 PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN
STEM CELL ASSAYS MARKET
12.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 372 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN
STEM CELL ASSAYS MARKET
12.7 COMPANY EVALUATION QUADRANT: STARTUPS/SMES
FIGURE 36 STEM CELL ASSAYS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2021
12.7.1 PROGRESSIVE COMPANIES
12.7.2 STARTING BLOCKS
12.7.3 RESPONSIVE COMPANIES
12.7.4 DYNAMIC COMPANIES
12.7.4.1 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 373 STEM CELL ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 374 STEM CELL ASSAYS MARKET: COMPETITIVE BENCHMARKING
OF KEY PLAYERS (STARTUPS/SMES)
12.8 COMPETITIVE SCENARIO AND TRENDS
12.8.1 PRODUCT LAUNCHES
TABLE 375 STEM CELL ASSAYS MARKET: PRODUCT LAUNCHES, JANUARY 2018-MAY 2022
12.8.2 DEALS
TABLE 376 STEM CELL ASSAYS MARKET: DEALS, JANUARY 2018-MAY 2022
12.8.3 OTHER DEVELOPMENTS
TABLE 377 STEM CELL ASSAYS MARKET: OTHER DEVELOPMENTS, JANUARY 2018-MAY 2022
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 THERMO FISHER SCIENTIFIC INC.
TABLE 378 THERMO FISHER SCIENTIFIC INC: BUSINESS OVERVIEW
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
13.1.2 MERK KGAA
TABLE 379 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2021)
13.1.3 DANAHER
TABLE 380 DANAHER: BUSINESS OVERVIEW
FIGURE 39 DANAHER: COMPANY SNAPSHOT (2021)
13.1.4 BECTON, DICKINSON AND COMPANY
TABLE 381 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 40 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
13.1.5 BIO-RAD LABORATORIES
TABLE 382 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 41 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.6 PERKINELMER INC.
TABLE 383 PERKINELMER INC.: BUSINESS OVERVIEW
FIGURE 42 PERKINELMER INC.: COMPANY SNAPSHOT (2021)
13.1.7 AGILENT TECHNOLOGIES, INC.
TABLE 384 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
13.1.8 BIO-TECHNE CORPORATION
TABLE 385 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
FIGURE 44 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2020)
13.1.9 FUJIFILM HOLDINGS CORPORATION
TABLE 386 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
13.1.10 CHARLES RIVER LABORATORIES
TABLE 387 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.11 LONZA GROUP
TABLE 388 LONZA GROUP: BUSINESS OVERVIEW
FIGURE 47 LONZA GROUP: COMPANY SNAPSHOT (2021)
13.1.12 PROMEGA CORPORATION
TABLE 389 PROMEGA CORPORATION: BUSINESS OVERVIEW
13.1.13 MILTENYI BIOTEC
TABLE 390 MILTENYI BIOTEC: BUSINESS OVERVIEW
13.1.14 STEMCELL TECHNOLOGIES
TABLE 391 STEMCELL TECHNOLOGIES: BUSINESS OVERVIEW
13.1.15 HEMOGENIX INC.
TABLE 392 HEMOGENIX INC.: BUSINESS OVERVIEW
13.1.16 CELL BIOLABS, INC.
TABLE 393 CELL BIOLABS, INC.: BUSINESS OVERVIEW
13.2 OTHER COMPANIES
13.2.1 TAKARA BIO INC.
13.2.2 CREATIVE BIOARRAY
13.2.3 AAT BIOQUEST, INC.
13.2.4 ABCAM PLC
13.2.5 BPS BIOSCIENCE, INC.
13.2.6 ENZO BIOCHEM INC.
13.2.7 PROMOCELL GMBH
13.2.8 BIOTIUM
13.2.9 GENO TECHNOLOGY INC.
13.2.10 REACHBIO RESEARCH LABS
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
